|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 1.440 USD | -1.37% |
|
-7.69% | -82.07% |
| 10-07 | Top Midday Gainers | MT |
| 10-07 | Lipocine Inc. Through Verity Pharmaceuticals Inc Announces Health Canada Approval of Tlando for Testosterone Replacement Therapy in Adult Males | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 11.87M | - | - | - | ||
| 64.69B | |||||
| 54.78B | |||||
| 53.49B | |||||
| 45.98B | |||||
| 42.94B |
- Stock Market
- Stocks
- LPCN Stock
- Charts Lipocine Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
